List of Excipients in Branded Drug BUSULFEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Otsuka America Pharmaceutical Inc	BUSULFEX	busulfan	59148-070	N,N-DIMETHYLACETAMIDE
Otsuka America Pharmaceutical Inc	BUSULFEX	busulfan	59148-070	POLYETHYLENE GLYCOL 400

Busulfex Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Busulfex is an intravenous busulfan product used in conditioning regimens before hematopoietic progenitor cell transplantation. Its commercial opportunity is driven less by molecule ownership and more by excipient safety, ready-to-use presentation, pediatric dosing, storage, supply reliability, and sterile manufacturing. The current formulation uses dimethylacetamide and polyethylene glycol 400, creating clear opportunities for lower-solvent, compatibility-enhanced, and operationally simpler alternatives.

What is Busulfex and how is it used?

Busulfex contains busulfan, an alkylating agent used as part of myeloablative conditioning before hematopoietic progenitor cell transplantation. The FDA-approved product is an intravenous concentrate supplied at 6 mg/mL and diluted before administration.[1]

The labeled regimen for adults commonly uses 0.8 mg/kg every six hours for 16 doses over four days, followed by cyclophosphamide or melphalan depending on the conditioning protocol. Pediatric dosing is based on body weight and requires individualized pharmacokinetic management in some patients.[1]

Attribute	Busulfex
Active ingredient	Busulfan
Route	Intravenous infusion
Dosage form	Sterile concentrate for dilution
Strength	6 mg/mL
Primary use	Conditioning before hematopoietic progenitor cell transplantation
Key excipients	Dimethylacetamide and polyethylene glycol 400
Diluent	0.9% sodium chloride or 5% dextrose solution
Therapeutic setting	Transplant centers and hospital oncology units
Product type	Small-molecule drug, not a biologic

Busulfex is not interchangeable with oral busulfan on a simple milligram-for-milligram basis. Intravenous administration reduces absorption variability and allows closer control of systemic exposure, which is important because busulfan has a narrow therapeutic range.

What excipients are used in Busulfex?

The formulation uses dimethylacetamide, commonly abbreviated DMA, and polyethylene glycol 400, commonly abbreviated PEG 400, as inactive ingredients.[1,2]

Dimethylacetamide

DMA is a polar organic solvent used to maintain busulfan solubility in the concentrated injection. Its formulation value is high, but it creates several commercial and regulatory considerations:

• Potential reproductive and developmental toxicity concerns
• Need for controlled occupational exposure during manufacturing
• Scrutiny of residual solvent levels
• Patient exposure concerns in pediatric and transplant populations
• Compatibility and extractables assessment for containers and administration sets
• Limited formulation flexibility because busulfan has low aqueous solubility

DMA is therefore both a functional excipient and a potential product-differentiation target.

Polyethylene glycol 400

PEG 400 supports solubilization and formulation stability. It is widely used in pharmaceutical products, but concentrated PEG systems can affect:

• Viscosity
• Dilution behavior
• Filtration performance
• Container closure compatibility
• Adsorption to administration components
• Osmolality and infusion tolerability

PEG 400 is generally more familiar to regulators than DMA, but its presence does not eliminate the need for extractables, leachables, and compatibility studies.

Dilution excipients

The commercial product is diluted before infusion in either 0.9% sodium chloride injection or 5% dextrose injection. A replacement formulation must preserve the labeled concentration, physical stability, infusion compatibility, and administration window after dilution.[1]

What excipient strategy offers the strongest commercial opportunity?

The strongest strategy is a lower-DMA or DMA-free intravenous formulation that preserves busulfan exposure while simplifying hospital preparation.

Strategy 1: Lower-DMA concentrate

A lower-DMA formulation would retain the existing concentrate model but reduce solvent exposure. This approach has the lowest development risk because it preserves the current clinical workflow.

Potential benefits include:

• Reduced patient exposure to DMA
• Easier toxicological justification
• Better positioning in pediatric transplantation
• Lower hazardous-solvent handling burden
• Potential differentiation from legacy and generic products

The main development constraint is busulfan solubility. Reducing DMA may require a co-solvent system, pH adjustment, complexation, surfactant use, or a different concentration.

Strategy 2: DMA-free ready-to-dilute injection

A DMA-free product could use a redesigned solvent system based on PEG 400, ethanol, propylene glycol, surfactants, cyclodextrins, or other solubilization technologies. Each option introduces its own safety and manufacturability questions.

A viable formulation would need to demonstrate:

• Adequate busulfan solubility at the labeled concentration
• Chemical stability through shelf life
• Physical stability after dilution
• No precipitation during refrigerated storage or infusion
• Low particulate burden
• Acceptable osmolality and infusion tolerability
• Compatibility with polyolefin bags, elastomeric closures, tubing, and filters
• Consistent exposure relative to the reference product

A DMA-free claim has commercial value only if the product remains operationally convenient. A formulation that requires complex reconstitution or short post-dilution stability may lose its advantage in transplant centers.

Strategy 3: Ready-to-use diluted infusion

A ready-to-use bag could remove pharmacy dilution steps and reduce preparation errors. The product could be supplied in a validated concentration and volume for adult or pediatric dosing.

This format would compete on workflow rather than molecule or patent exclusivity. Its development risks include:

• Larger shipping volume
• Greater container interaction risk
• Lower dose flexibility
• More complicated cold-chain requirements
• Shorter stability after manufacture
• Higher cost of goods
• Need for multiple presentations to cover weight-based dosing

The best commercial format may be a concentrated, low-DMA vial with extended post-dilution stability rather than a single fixed-dose bag.

Strategy 4: Pediatric-focused presentation

Pediatric transplantation is a strong target for excipient innovation because dose is weight-based and repeated administration is common. A lower-solvent formulation, smaller vial, or ready-to-use pediatric presentation could address institutional concerns about solvent exposure and dosing waste.

A pediatric product would need to support:

• Accurate low-volume dosing
• Minimal overfill and drug waste
• Reliable use in infusion pumps
• Compatibility with neonatal and pediatric tubing
• Clear concentration labeling
• Pharmacokinetic comparability across body-weight bands

What formulation patents could protect a Busulfex follow-on product?

A follow-on product would likely rely on formulation, manufacturing, and delivery claims rather than new chemical-entity claims.

Potential claim categories include:

Patent category	Possible claim focus
Solvent system	DMA-reduced or DMA-free busulfan compositions
Concentration	Higher or lower busulfan concentration with acceptable stability
Diluted product	Stable busulfan infusion in saline or dextrose
Container closure	Compatible vial, bag, syringe, or tubing system
Manufacturing	Sterile filtration, mixing, filling, or precipitation-control process
Storage	Refrigerated or room-temperature stability
Administration	Infusion protocol, dose preparation, or pharmacokinetic monitoring
Pediatric use	Weight-band dosing or reduced-solvent administration

Method-of-use claims may cover pharmacokinetic-guided dosing, conditioning combinations, or patient subgroups. Their value is generally narrower than composition claims because hospitals can often avoid them by using an alternative dosing protocol.

A meaningful patent position would require claims that survive obviousness challenges against legacy busulfan formulations, solvent systems, oncology infusion products, and published transplant protocols. A broad claim to busulfan with PEG 400 or DMA would face substantial prior-art pressure.

What is the Orange Book status of Busulfex?

Busulfex is an older small-molecule product, and its original active-ingredient, formulation, and regulatory exclusivities have expired. The central commercial question is therefore not basic molecule exclusivity but whether any unexpired, Orange Book-listed formulation or method-of-use patent remains relevant to the specific reference product and proposed ANDA label.[3]

An ANDA applicant would typically assess:

• Listed patents for the reference product
• Paragraph IV certification exposure
• Patent expiry and pediatric extensions
• Whether a proposed label overlaps a method-of-use patent
• Whether the product qualifies for 180-day generic exclusivity
• Whether the reference product has current commercial supply

The principal barrier is likely sterile injectable development rather than an active composition patent. Any current Orange Book assessment should be made against the FDA’s live listing because patent listings, delistings, and product marketing status can change.[3]

When does Busulfex lose exclusivity?

Busulfex’s core regulatory exclusivity has already expired because busulfan is an established active ingredient and the product was approved more than two decades ago. The relevant pathway for a competing product is generally an ANDA supported by pharmaceutical equivalence and bioequivalence or other applicable injectable-product requirements.

Busulfex does not create a biosimilar opportunity. Busulfan is a synthetic small molecule, so competitors would pursue generic, hybrid, or reformulated-drug pathways rather than the FDA biosimilar pathway.

A novel excipient system could be submitted under a 505(b)(2) application if the sponsor relies partly on the established busulfan product while introducing a clinically meaningful formulation change. An ANDA is more attractive if the formulation can meet the reference standard without requiring new clinical efficacy studies.

Which companies are challenging or competing with Busulfex?

Competition comes from generic busulfan injection products, oral busulfan, and alternative conditioning regimens rather than from biosimilars.

Competitive segment	Commercial effect
Generic IV busulfan	Price pressure and formulary substitution
Oral busulfan	Lower acquisition cost but greater absorption variability
Other conditioning agents	Protocol-level substitution, particularly in transplant centers
Novel IV busulfan formulation	Potential premium through safety and workflow benefits
Hospital-compounded preparation	Possible low-cost alternative but with operational and quality limitations

The key competitors are manufacturers with sterile injectable capacity, validated oncology product lines, and access to transplant-center procurement channels. A company with a strong excipient platform can compete even without owning a valuable busulfan patent estate.

What patent litigation and Paragraph IV risks exist?

The most likely litigation risk for a generic Busulfex entrant would arise from a Paragraph IV certification against any unexpired formulation or method-of-use patent listed for the reference product. Product-specific litigation cannot be inferred from the molecule’s age alone.

For a reformulated entrant, the litigation profile changes:

• A DMA-free product may avoid claims limited to the legacy solvent system.
• A ready-to-use product may create new formulation claims.
• A lower-strength or pediatric product may reduce overlap with existing claims.
• A 505(b)(2) product may face patent litigation and regulatory exclusivity claims even if it is not an ANDA.

The strongest defensive position would combine a composition patent with manufacturing and container-compatibility claims. Manufacturing-only claims are less effective if competitors can use a different process.

How strong is the Busulfex patent estate?

The legacy Busulfex patent estate is commercially weak relative to a newly developed formulation estate because the active ingredient and clinical use are old. Any remaining protection is more likely to involve a narrow formulation, process, or use claim than broad control over busulfan.

Patent strength for a new product would depend on:

1. Whether the solvent system is compositionally distinct.
2. Whether the formulation solves a documented stability or safety problem.
3. Whether the claims cover the product as sold, not only an internal manufacturing step.
4. Whether the formulation supports a non-obvious clinical or operational benefit.
5. Whether the patent term extends far enough to cover launch and commercialization.

A sponsor should prioritize claims that cover the commercial vial, diluted infusion, container system, and preparation process.

What FDA regulatory strategy is available for a new excipient formulation?

The regulatory route depends on the degree of formulation change.

ANDA

An ANDA is appropriate for a product that is pharmaceutically equivalent to the reference product and can meet applicable quality and bioequivalence requirements. This route generally offers the lowest development cost but limits differentiation.

505(b)(2)

A 505(b)(2) application is more suitable for a DMA-free, ready-to-use, pediatric, or otherwise clinically distinct product. The sponsor could rely on FDA findings for busulfan while generating new data for formulation safety, pharmacokinetics, stability, and administration.

FDA excipient considerations

A new or materially different excipient system would require assessment of:

• Route-specific prior use
• Maximum daily exposure
• Toxicology
• Reproductive and developmental toxicity
• Impurity profile
• Extractables and leachables
• Residual solvents
• Infusion compatibility
• Stability-indicating analytical methods

The use of an excipient with limited prior intravenous exposure would materially increase the regulatory burden.

What commercial opportunities exist for Busulfex reformulation?

The most defensible commercial opportunities are operational and safety-based.

Opportunity	Customer value	Development attractiveness
Lower-DMA concentrate	Reduces solvent exposure while preserving workflow	High
DMA-free formulation	Strong differentiation and pediatric positioning	Medium
Ready-to-dilute vial	Reduces pharmacy preparation steps	High
Ready-to-use bag	Reduces compounding burden	Medium
Smaller pediatric vial	Reduces waste and dosing errors	Medium to high
Extended post-dilution stability	Improves scheduling and inventory control	High
Container-optimized product	Reduces adsorption and compatibility concerns	Medium
Supply-secure generic	Supports formulary continuity	High

Revenue exposure is concentrated in transplant centers, where procurement decisions are influenced by product availability, pharmacy labor, dosing reliability, and institutional protocols. Public filings generally do not provide standalone Busulfex revenue, so product-level revenue cannot be calculated from issuer disclosures alone. The addressable market is narrower than the broader oncology market but can support premium pricing if a product solves a recognized pharmacy or safety problem.

What generic launch scenarios exist for Busulfex?

Commodity generic launch

A conventional generic injectable competes primarily on price and supply. It faces limited patent risk but must manage sterile manufacturing, validation, and hospital contracting.

Premium differentiated launch

A low-DMA or DMA-free formulation could command a premium if supported by clinical pharmacokinetic comparability and transplant-center adoption.

Shortage-response launch

A sponsor could enter when branded or generic supply is constrained. This strategy depends on manufacturing readiness, FDA approval, and reliable active pharmaceutical ingredient supply.

Pediatric specialty launch

A pediatric presentation could target transplant hospitals with lower-volume but higher service requirements. The product would need strong dosing, packaging, and pharmacokinetic support.

What manufacturing and IP barriers affect commercial entry?

The major barriers are technical:

• Busulfan solubility at clinically useful concentrations
• Sterile filtration without precipitation or adsorption
• Control of DMA and other solvent impurities
• Container compatibility
• Stability after dilution
• Low-particulate injectable manufacturing
• Consistent assay and impurity control
• Supply of pharmaceutical-grade busulfan
• Validation of repeated-dose preparation

These barriers favor established sterile-injectable manufacturers and contract development and manufacturing organizations with oncology experience. A formulation patent without dependable fill-finish capacity has limited commercial value.

Key Takeaways

• Busulfex uses busulfan with DMA and PEG 400 in a sterile intravenous concentrate.
• The best excipient opportunity is a lower-DMA formulation that preserves the existing hospital workflow.
• A DMA-free product offers stronger differentiation but carries greater solubility, toxicology, and regulatory risk.
• Busulfan is a small molecule, so biosimilar competition is irrelevant.
• Core product exclusivity has expired; generic entry is constrained mainly by sterile manufacturing and formulation complexity.
• An ANDA is suitable for a conventional equivalent product. A 505(b)(2) pathway is more suitable for a clinically differentiated formulation.
• The most valuable patent claims would cover the commercial composition, diluted infusion, container system, and manufacturing process.
• Commercial value is concentrated in transplant-center procurement, pediatric dosing, preparation efficiency, and supply reliability.

FAQs

Can Busulfex be reformulated without dimethylacetamide?

Yes, but the sponsor must solve busulfan’s limited aqueous solubility while maintaining stability, sterility, dilution performance, and comparable pharmacokinetics.

Is PEG 400 safe for intravenous Busulfex formulations?

PEG 400 has established pharmaceutical use, but the sponsor must justify the route-specific exposure, concentration, impurity profile, and compatibility of the complete formulation.

Does a DMA-free Busulfex formulation need new clinical trials?

Not necessarily. The data package depends on the regulatory pathway and the extent of the formulation change. A 505(b)(2) product would normally require formulation-specific pharmacokinetic and safety support.

Can a generic manufacturer sell busulfan in a ready-to-use infusion bag?

Potentially. The product would need to meet FDA requirements for injectable quality, stability, container compatibility, labeling, and the selected regulatory pathway.

What is the most attractive licensing opportunity in Busulfex?

The strongest licensing target is a validated low-DMA or DMA-free busulfan formulation paired with sterile fill-finish capacity, pediatric dosing data, and extended post-dilution stability.

References

1. U.S. Food and Drug Administration. (2019). Busulfex (busulfan) injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020954s012lbl.pdf

2. National Library of Medicine. (n.d.). Busulfex - busulfan injection, solution. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm